3. GlaxoSmithKline - Top 15 R&D Budgets

Who: GlaxoSmithKline

Based: United Kingdom

2006 Pipeline Budget: $7.51 billion (€5.13B)

Pipeline News:
GSK had its share of problems this year as safety concerns took a big bite out of Avandia--a blockbuster diabetes drug--sales. The company also fended off riled investors who've been displeased with GSK's lackluster stock performance. In addition, several big GSK drugs, including Wellbutrin XL, Coreg IR, and Zofran--are facing generic competition. However, over the long term, things don't look so bad. The company has an incredible 33 drugs in Phase III development (three times as many as Pfizer) and could launch as many as 25 new drugs over the next two years. GSK is also ramping up marketing of Alli, Cervarix and Tykreb.

Pending Approval:
> Avandia + simvastatin - Type 2 diabetes
> Hycamtin - small cell lung cancer, second-line therapy (oral formulation
> Globorix - diptheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b disease, Neisseria meningitis groups A & C disease prophylaxis
> Infanrix-IPV/Kinrix - Diptheria, tetanus, pertussis and poliomyelitis prophylaxis
> Flu pre-pandemic H5N1 - Pandemic influenza prophylaxis
> Entereg/Entrareg - Post operative ileus Approvable
> Gepirone ER - major depressive disorder, once-daily
> Lamictal XR - Epilepsy
> ReQuip XR - Restless legs syndrome
> Trexima - Migraine

Phase III Pipeline:

> Coreg CR† + ACE - hypertension
> Avandamet XR - Type 2 diabetes
> Avandia - Type 2 diabetes, Prevention of diabetes
> Dacart - Uncomplicated malaria
> Hycamtin - Ovarian cancer, first-line therapy
> Ofatumumab - Chronic lymphocytic leukaemia (also rheumatoid arthritis), follicular lymphoma
> Pazopanib - Renal cell cancer
> Promacta/Revolade - Long-term idiopathic thrombocytopaenic purpura, short-term idiopathic thrombocytopaenic purpura
> Rezonic/Zunrisa - chemotherapy-induced & postoperative nausea & vomiting (also depression & anxiety)
> Tykerb/Tyverb ErbB-2 and EGFR - breast cancer, breast cancer brain metastases, breast cancer (first-line therapy), head & neck squamous cell carcinomas
> Hib-MenCY-TT - Neisseria meningitis groups C & Y disease & Haemophilus influenzae type b disease prophylaxis
> MenACWY-TT - Neisseria meningitis groups A, C, W and Y disease prophylaxis
> Synflorix - Streptococcus pneumoniae & non-typable Haemophilus influenzae disease prophylaxis for children
> MAGE-A3 - Non-small cell lung cancer
> Avodart - Reduction in the risk of prostate cancer
> Avodart + alpha blocker - benign prostatic hyperplasia
> Belimumab - Systemic lupus erythematosus
> Bosatria - Hypereosinophilic syndrome (also severe asthma & nasal polyposis)
> Entereg/Entrareg - Opioid-induced bowel dysfunction
> 1838262 - Restless legs syndrome
> Lamictal XR - Partial generalised tonic-clonic seizures, once-daily
> Rosiglitazone XR - Alzheimer's disease

Full Pipeline Site: Link

3. GlaxoSmithKline - Top 15 R&D Budgets

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i